Arvinas Inc logo

ARVN - Arvinas Inc Share Price

$50.27 -0.5  -1.0%

Last Trade - 5:11pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.49bn
Enterprise Value £1.35bn
Revenue £31.8m
Position in Universe 1951st / 6416
Bullish
Bearish
Unlock ARVN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARVN Revenue Unlock ARVN Revenue

Net Income

ARVN Net Income Unlock ARVN Revenue

Normalised EPS

ARVN Normalised EPS Unlock ARVN Revenue

PE Ratio Range

ARVN PE Ratio Range Unlock ARVN Revenue

Dividend Yield Range

ARVN Dividend Yield Range Unlock ARVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARVN EPS Forecasts Unlock ARVN Revenue
Profile Summary

Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Company is using its PROTAC platform to build an pipeline of protein degradation product candidates to target diseases in a wide range of organ systems and tissues. It is also focused on advancing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. It seeks to initiate a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), and a Phase 1 clinical trial for ARV-471 in women with metastatic ER positive, HER2 negative breast cancer, or ER+ breast cancer.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated December 9, 2014
Public Since September 27, 2018
No. of Shareholders: 120
No. of Employees: 103
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 38,293,907
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARVN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARVN
Upcoming Events for ARVN
Similar to ARVN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.